SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab

Detalles Bibliográficos
Autores principales: Stiasny, Karin, Weseslindtner, Lukas, Heinzel, Andreas, Camp, Jeremy V., Oberbauer, Rainer, Reindl-Schwaighofer, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Health Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790897/
https://www.ncbi.nlm.nih.gov/pubmed/36578452
http://dx.doi.org/10.3389/ti.2022.10906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790897/
https://www.ncbi.nlm.nih.gov/pubmed/36578452
http://dx.doi.org/10.3389/ti.2022.10906

Ejemplares similares